NBOCA’s policy is that data on colorectal cancer outcomes during the COVID-19 pandemic and the subsequent recovery phase will not be used for benchmarking or assessment of hospital trusts and MDTs.

2023 outlier-reporting:
The only NBOCA trust/MDT outcome which will be outlier reported in 2023 is risk-adjusted 2-year mortality in patients having surgery 1 Apr 2019 – 31 Mar 2020. 2-year mortality is an important indicator of the overall quality of care provided by a colorectal cancer MDT. Given the importance of this indicator we plan to begin reporting risk-adjusted 2-year mortality for patients having major surgery as the first indicator re-introduced following COVID-19 pandemic and recovery period.

Outlier reporting from 2024:
From 2024 reporting onwards, outlier reporting will resume for all of the NBOCA trust/MDT outcomes.

NBOCA retains the same core team and now resides within the National Cancer Audit Collaborating Centre (NATCAN) at the Royal College of Surgeons of England (RCS England). NATCAN includes three established cancer audits and six newly commissioned cancer audits.

Data submission for patients diagnosed with colorectal cancer before 31 March 2022 should have already been checked for accuracy and completeness and will inform the 2023 NBOCA Annual Report.

The new NBOCA commission has a commitment to reducing administrative burdens on colorectal cancer MDTS with immediate effect and future reporting will utilise robust data from existing national datasets. Reporting will be based on institution level data provided to the National Disease Registration Service (NDRS) and linked to other national datasets. NBOCA still encourages clinicians to engage with coders and data administrators to ensure data accuracy, especially on staging information provided to NDRS.

NBOCA will also have similar access to collated national Welsh colorectal cancer data from the Cancer Information System for Wales that will shortly replace the Cancer Network Information System Cymru (CaNISC).

NBOCA will continue to focus on robust reporting of data for all patient with colorectal cancer, earlier availability in reporting outcomes, and a major ongoing emphasis on implementation of quality improvement initiatives.

This short report can be accessed here.

Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study

Access here

The fellowship provides a unique opportunity to work at the Clinical Effectiveness Unit of the Royal College of Surgeons of England, within a multidisciplinary team, delivering a national audit and carrying out research whilst developing advanced analysis and research skills. The post-holder is expected to lead on the writing of journal articles and conference presentations and work towards either an MD or PhD with the support of senior colleagues at the CEU.

The closing date for applications is 1 June 2021. For more information and to apply go to:

RCS vacancies

Ms Nicola Fearnhead, Clinical Lead and Immediate Past President of the ACPGBI says
“Research during surgical or oncology training provides a unique opportunity to do a deep dive. Immerse yourself. This is when we really understand the challenges facing both clinicians and researchers. Knowing the challenges brings us together to collate and interpret data in meaningful ways. It gives us the best chance of improving outcomes and experience for patients with colorectal cancer. Making a meaningful impact is what we at NBOCA do, and our next Research Fellow will be an integral part of our patient-focussed team.”

NBOCA understands that the coming months are going to be difficult for clinicians and MDTs to provide care to patients with bowel cancer during the COVID-19 pandemic. Providing systemic anticancer therapy and radiotherapy and undertaking surgical resections will be challenging. Treatment pathways will be altered to avoid patients becoming immunosuppressed or having to access hospital-based care, both of which would increase their risk of serious illness from COVID-19. Restricted access to theatres and critical care beds may also result in delays.  Patients admitted for surgery will be at risk of contracting COVID-19 while in hospital and of adverse outcomes both due to the disease and potential lack of critical care resources.

The information on care pathways, surgical activity and outcomes routinely produced by the National Bowel Cancer Audit will undoubtedly show the impact of COVID-19 on the delivery of bowel cancer services.  As such, the audit team has begun to review its statistical methods so that the impact of COVID-19 can be identified and distinguished from the typical results produced by hospital trusts and surgeons.  This will ensure the Audit can help the surgical community and wider health system learn valuable lessons from this unprecedented time.  It will also ensure that, once the pandemic is over, information produced by the Audit for hospital trusts and surgeons gives an accurate reflection of the likely outcomes for patients under normal circumstances, unbiased by the impact on outcomes during the pandemic.

In summary:

  • Please continue to collect NBOCA data locally during the COVID-19 pandemic so that we can understand the impact of the pandemic on the provision of cancer services.
  • The NBOCA CAP system remains open for data submissions and NBOCA can provide help.  There will be no data submission deadlines during this unprecedented period.
  • Data on colorectal cancer outcomes during COVID-19 and the subsequent recovery phase will not be used for benchmarking or assessment of hospital trusts and MDTs, and nor will it be used towards Clinical Outcomes Publication.
  • Information produced by the Audit will accurately reflect the outcomes for patients under normal circumstances.

Take a look at the most up to date information regarding the care and outcomes of patients with bowel cancer in England and Wales. The 2019 Annual Report, the Patient Report, Organisational Survey, and a table of the Trust Results are all available at Reports.

The results for individual trusts are available at Trust results.

The results will be added to the Trust Results pages of this website in January 2018.

For the 2018 annual report the first data submission deadline is 6 October 2017. The second data submission deadline for allowing patients to be linked to HES/PEDW and ONS mortality data is 26 January 2018. Initial results will be sent to trusts after this deadline so that any incomplete or incorrect data can be updated. Any new cases added after the 26 January deadline cannot be included in the outcomes for outlier reporting in the 2018 Annual Report or Clinical Outcomes Publication because they will not be linked to HES/PEDW or ONS mortality data.

Patients submitted by the initial data submission deadline earlier in the year were linked to ONS mortality data and Hospital Episode Statistics data (HES) and can therefore be included in risk-adjusted outcomes reporting.

The data is currently being analysed and will be used to produce the 2017 annual report, due to be published in December 2017, and the Clinical Outcome Publication, due to be published on the ACPGBI website in November 2017.